XERS today
$16.69+$0.04 (+0.24%)close Nov 13, 2026Trend
DailyUptrend (confirmed)
4 hourLeaning Bearish
1 hourStrong Bullish
15 minBullish
5 minBullish
Daily trend turns down below $9.04
Key levels
Resistance$18.88
Resistance$17.38
Support$16.57
Support$15.29
Latest news & SEC filings
AnalystBarclays keeps Overweight rating on Xeris Biopharma, lifts target to $18
NewsXeris Biopharma insider sells shares valued at $312,215
AnalystOppenheimer lifts its target for Xeris Biopharma shares to $21
SEC FilingXeris Biopharma Holdings, Inc. filed an insider trading report (Form 4)
All XERS news →About Xeris Biopharma
Xeris Biopharma is a drugmaker that sells medicines in the United States for long-term hormonal and nervous-system disorders. Its three approved therapies treat excess cortisol, dangerously low blood sugar, and a rare muscle paralysis condition. The company also develops injectable formulations based on its water-free delivery platforms, including a weekly under-the-skin thyroid hormone candidate, and partners with other pharmaceutical firms on formulation work.
Based on the company's 10-K filed Mar 2, 2026.
Nasdaq · Healthcare
Xeris Biopharma Holdings, Inc. (XERS)
What Is the Price Target for XERS?
SEPT Low Target
$12.00
SEPT Mid Target
$18.00
SEPT High Target
$21.00
Analyst Consensus
$18.00
Is XERS a Buy or Sell Right Now?
Thesis
- •Revenue growing 43.7% YoY with STRONG trend — consistent growth.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment rising.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for XERS.
Start Free Trial →Is XERS Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$12.12
19
Moat Score
NONE
7/9
Piotroski Score
3.4
Altman Z-Score
What Is Smart Money Doing with XERS?
Insider Signal
SELLING
0 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| McCulloch Kevin | officer | Sale | 25,000 | $312K | Nov 5, 2026 |
| Hecht Beth | officer | Sale | 25,000 | $256K | Nov 2, 2026 |
| Taddese Menassie | director | Buy | 22,365 | - | Nov 2, 2026 |
| Pieper Steven | officer | Sale | 5,000 | $51K | Nov 2, 2026 |
| McCulloch Kevin | officer | Sale | 15,000 | $153K | Nov 2, 2026 |
| Hecht Beth | officer | Sale | 16,666 | $157K | Oct 1, 2026 |
| McCulloch Kevin | officer | Sale | 25,000 | $250K | Sep 28, 2026 |
| Hecht Beth | officer | Sale | 16,666 | $141K | Sep 1, 2026 |
| McCulloch Kevin | officer | Sale | 15,000 | $127K | Sep 1, 2026 |
| Pieper Steven | officer | Sale | 5,000 | $43K | Sep 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →XERS Growth Story
Revenue YoY
43.7%
3yr Revenue CAGR
38.3%
EPS Growth YoY
100%
FCF Growth YoY
N/A%
Revenue Trend
STRONG
Dark Pool Trades for XERS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for XERS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:29:47 | $16.73 | 1,546 | $$26K | SELL |
| 18:29:47 | $16.73 | 2,311 | $$39K | SELL |
| 18:23:40 | $16.70 | 2,400 | $$40K | MIDPOINT |
| 18:11:06 | $16.72 | 3,000 | $$50K | MIDPOINT |
| 18:08:34 | $16.70 | 1,000 | $$17K | BUY |
5 dark pool trades shown · $$171K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for XERS
PREVIEWSEPT Investing provides real-time options flow tracking for XERS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $12 | Dec 18 | 35 | $$240 | 16 | SWEEP |
| PUT | $12 | Dec 18 | 35 | $$15 | 1 | SWEEP |
| CALL | $14 | Nov 20 | 7 | $$270 | 1 | SWEEP |
| CALL | $20 | Jan 15 | 63 | $$65 | 1 | SWEEP |
4 options trades shown · 50% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About XERS
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for XERS. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $XERS -- Neutral XERS breakout at $7.92. Day range $7.70-$7.96. Price testing zone top $7.96. Break above with volume = breakout. Above $7.96, next zone $8.12. The Play: Three scenario...
Join 3,500+ traders discussing XERS in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Xeris Biopharma Holdings, Inc. (XERS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →XERS — frequently asked questions
What is XERS stock price today?
Xeris Biopharma Holdings, Inc. (XERS) is at $16.69, up 0.24% (+$0.04) at the Nov 13, 2026 close.
Why is XERS stock moving today?
Latest XERS news — Nov 11, 2026: Barclays keeps Overweight rating on Xeris Biopharma, lifts target to $18 · Nov 7, 2026: Xeris Biopharma insider sells shares valued at $312,215
Why did XERS stock move on Nov 5, 2026?
Xeris Biopharma reported Q3 2026 adjusted EPS of $0.06 and sales of $106.267 million, both beating analyst estimates, and raised its full-year 2026 sales outlook to $395M-$405M from a prior $385M-$390M range. The company also projected fiscal 2030 revenue above $1 billion, up from its previous $750 million forecast.
What is the XERS price target?
The average analyst price target for XERS is $18.00, ranging from $12 to $21, based on 5 analysts. Latest: Barclays maintains on Nov 11, 2026.
What do analysts rate XERS?
Analyst ratings for XERS: 0 Buy, 7 Hold, 0 Sell — consensus Hold.
Did XERS beat earnings?
XERS last reported on Nov 5, 2026: EPS $0.06 vs $0.03 expected — a beat of 89.3%.
Does XERS pay a dividend?
XERS does not currently pay a dividend.
How much debt does XERS have?
Xeris Biopharma Holdings, Inc. reported $190M of debt and $131M of cash (Sep 30, 2026).
What are XERS support and resistance levels?
Support: $16.57, $15.29, $12.94. Resistance: $17.38, $18.88, $20.28.
What are insiders doing with XERS?
Insider activity: SELLING, 0 buys and 13 sells in the last 90 days.
What is the latest news on XERS?
Nov 11, 2026: Barclays keeps Overweight rating on Xeris Biopharma, lifts target to $18 · Nov 7, 2026: Xeris Biopharma insider sells shares valued at $312,215 · Nov 6, 2026: Oppenheimer lifts its target for Xeris Biopharma shares to $21